|
|
 | | | |
- close
- close
- close
- close
Valeant Pharmaceuticals International (VRX) |
Market Intelligence Center
May 22
Comment
Valeant Pharmac. (NYSE: VRX) closed Tuesday's trading session at $75.53. In the past year, the stock has hit a 52-week low of $42.47 and 52-week high of $78.69. Valeant Pharmac. (VRX) stock has been showing support around $73.42 and resistance in...
Stock Blog Hub
May 16
Comment
Valeant Pharmaceuticals’ (VRX) first quarter 2013 earnings of $1.27 (excluding special items but including stock-based compensation expense) were short of the Zacks Consensus Estimate by a penny but were up from the year-ago earnings of 1.08 per...
Market Intelligence Center
May 16
Comment
Valeant Pharmac. (NYSE: VRX) closed Wednesday's trading session at $76.33. In the past year, the stock has hit a 52-week low of $42.47 and 52-week high of $77.44. Valeant Pharmac. (VRX) stock has been showing support around $74.67 and resistance...
Wall Street Journal
May 15
Comment
A heated takeover battle has erupted around generic-drug company Actavis. Novartis is considering whether to enter the fray, while Valeant and Mylan are evaluating their options after approaches they made for Actavis were rebuffed.
FiercePharma
May 13
Comment
While Valeant Pharmaceuticals was chatting up Actavis about a potential merger-of-equals, Actavis was apparently mulling a bid for Warner Chilcott, the Irish drugmaker that specializes in women's health and dermatology.
Market Intelligence Center
May 3
Comment
Valeant Pharmac. (NYSE: VRX) closed Thursday's trading session at $72.15. In the past year, the stock has hit a 52-week low of $42.47 and 52-week high of $76.57. Valeant Pharmac. (VRX) stock has been showing support around $70.12 and resistance in...
Benzinga
May 3
Comment
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that we agreed this afternoon that the launch of efinaconazole, our topical product candidate for the treatment of onychomycosis, will not occur until after the September 2013...
Benzinga
May 2
Comment
Anacor Pharmaceuticals (NASDAQ: ANAC) today announced that Valeant
Pharmaceuticals International, Inc. (NYSE: VRX), or Valeant, has agreed that the launch of
efinaconazole, its topical product candidate for the treatment of
onychomycosis, will...
Reuters
May 2
Comment
* First-quarter net loss $0.09/share vs $0.04 year earlier * Total revenue rises 25 percent * Sees 2013 cash EPS $5.55-$5.85 vs prior fcast $5.45-$5.75 By Rod Nickel and Bhaswati Mukhopadhyay May 2...
Reuters
May 2
Comment
Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Thursday that the company would focus on acquisitions with strong cash flow in...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
